162 related articles for article (PubMed ID: 36127700)
1. STMN1 as a novel prognostic biomarker in HCC correlating with immune infiltrates and methylation.
Zhang ED; Li C; Fang Y; Li N; Xiao Z; Chen C; Wei B; Wang H; Xie J; Miao Y; Zeng Z; Huang H
World J Surg Oncol; 2022 Sep; 20(1):301. PubMed ID: 36127700
[TBL] [Abstract][Full Text] [Related]
2. The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma.
Chen YL; Uen YH; Li CF; Horng KC; Chen LR; Wu WR; Tseng HY; Huang HY; Wu LC; Shiue YL
Ann Surg Oncol; 2013 Nov; 20(12):4041-54. PubMed ID: 22911364
[TBL] [Abstract][Full Text] [Related]
3. STMN1 upregulation mediates hepatocellular carcinoma and hepatic stellate cell crosstalk to aggravate cancer by triggering the MET pathway.
Zhang R; Gao X; Zuo J; Hu B; Yang J; Zhao J; Chen J
Cancer Sci; 2020 Feb; 111(2):406-417. PubMed ID: 31785057
[TBL] [Abstract][Full Text] [Related]
4. Stathmin 1 is a biomarker for diagnosis of microvascular invasion to predict prognosis of early hepatocellular carcinoma.
Cai Y; Fu Y; Liu C; Wang X; You P; Li X; Song Y; Mu X; Fang T; Yang Y; Gu Y; Zhang H; He Z
Cell Death Dis; 2022 Feb; 13(2):176. PubMed ID: 35210426
[TBL] [Abstract][Full Text] [Related]
5. Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma.
Hsieh SY; Huang SF; Yu MC; Yeh TS; Chen TC; Lin YJ; Chang CJ; Sung CM; Lee YL; Hsu CY
Mol Carcinog; 2010 May; 49(5):476-87. PubMed ID: 20232364
[TBL] [Abstract][Full Text] [Related]
6.
Imura S; Yamada S; Saito YU; Iwahashi S; Arakawa Y; Ikemoto T; Morine Y; Utsunomiya T; Shimada M
Anticancer Res; 2017 Oct; 37(10):5877-5883. PubMed ID: 28982915
[TBL] [Abstract][Full Text] [Related]
7. Thyroid hormone suppresses expression of stathmin and associated tumor growth in hepatocellular carcinoma.
Tseng YH; Huang YH; Lin TK; Wu SM; Chi HC; Tsai CY; Tsai MM; Lin YH; Chang WC; Chang YT; Chen WJ; Lin KH
Sci Rep; 2016 Dec; 6():38756. PubMed ID: 27934948
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of Stathmin 1 correlates with poor prognosis and promotes cell migration and proliferation in oesophageal squamous cell carcinoma.
Ni PZ; He JZ; Wu ZY; Ji X; Chen LQ; Xu XE; Liao LD; Wu JY; Li EM; Xu LY
Oncol Rep; 2017 Dec; 38(6):3608-3618. PubMed ID: 29039594
[TBL] [Abstract][Full Text] [Related]
9. Stathmin 1 promotes the progression of liver cancer through interacting with YAP1.
Liu YP; Pan LL; Kong CC
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7335-7344. PubMed ID: 32706072
[TBL] [Abstract][Full Text] [Related]
10. An Immunohistochemical Study of Stathmin 1 Expression in Osteosarcoma Shows an Association with Metastases and Poor Patient Prognosis.
Zhao C; Li H; Wang L; Sun W
Med Sci Monit; 2018 Aug; 24():6070-6078. PubMed ID: 30169496
[TBL] [Abstract][Full Text] [Related]
11. Aberrantly high activation of a FoxM1-STMN1 axis contributes to progression and tumorigenesis in FoxM1-driven cancers.
Liu J; Li J; Wang K; Liu H; Sun J; Zhao X; Yu Y; Qiao Y; Wu Y; Zhang X; Zhang R; Yang A
Signal Transduct Target Ther; 2021 Feb; 6(1):42. PubMed ID: 33526768
[TBL] [Abstract][Full Text] [Related]
12. A Bioinformatics Analysis Identifies the Telomerase Inhibitor MST-312 for Treating High-STMN1-Expressing Hepatocellular Carcinoma.
Wang SJ; Yang PM
J Pers Med; 2021 Apr; 11(5):. PubMed ID: 33922244
[TBL] [Abstract][Full Text] [Related]
13. Karyopherin α2-dependent import of E2F1 and TFDP1 maintains protumorigenic stathmin expression in liver cancer.
Drucker E; Holzer K; Pusch S; Winkler J; Calvisi DF; Eiteneuer E; Herpel E; Goeppert B; Roessler S; Ori A; Schirmacher P; Breuhahn K; Singer S
Cell Commun Signal; 2019 Nov; 17(1):159. PubMed ID: 31783876
[TBL] [Abstract][Full Text] [Related]
14. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
15. High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma.
Bao P; Yokobori T; Altan B; Iijima M; Azuma Y; Onozato R; Yajima T; Watanabe A; Mogi A; Shimizu K; Nagashima T; Ohtaki Y; Obayashi K; Nakazawa S; Bai T; Kawabata-Iwakawa R; Asao T; Kaira K; Nishiyama M; Kuwano H
Ann Surg Oncol; 2017 Dec; 24(13):4017-4024. PubMed ID: 28933054
[TBL] [Abstract][Full Text] [Related]
16. The relationship among Girdin DNA methylation, its high expression, and immune infiltration in hepatocellular carcinoma: Clues from in silico analysis.
Zhang C; Ke Y; Lei X; Liu X; Li H; Shi R; Wang L
Biosci Rep; 2021 Mar; 41(3):. PubMed ID: 33660763
[TBL] [Abstract][Full Text] [Related]
17. Elevated STMN1 Expression Correlates with Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma.
Li J; Hu G; Kong F; Wu K; Song K; He J; Sun W
Pathol Oncol Res; 2015 Sep; 21(4):1013-20. PubMed ID: 25791566
[TBL] [Abstract][Full Text] [Related]
18. STMN1 is Overexpressed in Adrenocortical Carcinoma and Promotes a More Aggressive Phenotype In Vitro.
Aronova A; Min IM; Crowley MJP; Panjwani SJ; Finnerty BM; Scognamiglio T; Liu YF; Whitsett TG; Garg S; Demeure MJ; Elemento O; Zarnegar R; Fahey TJ
Ann Surg Oncol; 2018 Mar; 25(3):792-800. PubMed ID: 29214451
[TBL] [Abstract][Full Text] [Related]
19. Prognostic potential of the small GTPase Ran and its methylation in hepatocellular carcinoma.
Liu HH; Wang J; Zhang Y; Fan YC; Wang K
Hepatobiliary Pancreat Dis Int; 2022 Jun; 21(3):248-256. PubMed ID: 35367146
[TBL] [Abstract][Full Text] [Related]
20. High MCM8 expression correlates with unfavorable prognosis and induces immune cell infiltration in hepatocellular carcinoma.
Yu M; Wang H; Xu H; Lv Y; Li Q
Aging (Albany NY); 2022 Dec; 14(24):10027-10049. PubMed ID: 36575045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
